Macular Degeneration Stem Cell Treatment

Macular Degeneration and Stem Cell Therapy

What is Macular Degeneration?

Macular Degeneration and Stem Cell Therapy

Macular Degeneration and Stem Cell Therapy


Macular Degeneration or Age Related Macular Degeneration (AMD,ARMD) is a eyesight condition which mostly affects older people. AMD results in a loss of vision in the center of the visual field (the macula) because of damage or wear to the retina.

AMD can occur in either a wet or dry types. AMD is a major cause of visual impairment in people of 50 years age or more. AMD can make it difficult or impossible to read or to be able to recognize faces, although enough peripheral vision can remain to allow normal daily life.
 
Although some macular dystrophies that younger people get are referred to as macular degeneration, the term generally refers to age-related macular degeneration.

 

Stemming vision loss with stem cells.

J Clin Invest. 2010 Sep 1;120(9):3012-21

Authors: Marchetti V, Krohne TU, Friedlander DF, Friedlander M

Dramatic advances in the field of stem cell research have raised the possibility of using these cells to treat a variety of diseases. The eye is an excellent target organ for such cell-based therapeutics due to its ready accessibility, the prevalence of vasculo- and neurodegenerative diseases affecting vision, and the availability of animal models to demonstrate proof of concept. In fact, stem cell therapies have already been applied to the treatment of disease affecting the ocular surface, leading to preservation of vision. Diseases in the back of the eye, such as macular degeneration, diabetic retinopathy, and inherited retinal degenerations, present greater challenges, but rapidly emerging stem cell technologies hold the promise of autologous grafts to stabilize vision loss through cellular replacement or paracrine rescue effects.

PMID: 20811157 [PubMed - indexed for MEDLINE]

Related Articles Assessing "cell therapy" clinics offering treatments of ocular conditions using direct-to-consumer marketing websites in the United States. Ophthalmology. 2019 Mar 20;: Authors: Nirwan RS, Albini TA, Sridhar J, Flynn HW, Kuriyan AE Abstract PURPOSE: "Cell therapy" is becoming increasingly available to the public via online direct-to-consumer advertisement within the United States (U.S.). The current study investigates the scope of "cell therapy" clinics across the U.S. that advertise and offer "cell therapy" for ocular conditions based on information provided on their websites. DESIGN: A cross-sectional study. SUBJECTS, PARTICIPANTS, AND/OR CONTROLS: The study included companies that are U.S.-based, participate in direct-to-consumer online marketing, have websites that can be data-mined with content analysis, and advertise therapy for ocular conditions. METHODS: Using a systematic, extensive keyword-based Internet search, content analysis of company websites was utilized to identify, document, and analyze U.S. businesses marketing "cell therapy" for ocular conditions as of September 16th, 2017. MAIN OUTCOME MEASURES: Clinic locations, source of stem cells used, route of administration, marketed ocular conditions, and cost of treatment. RESULTS: Forty companies with 76 clinics use "cell therapy" to treat ocular conditions. California (23), Florida (12), and Illinois (10) contain the most clinics. All 40 companies specified sources of cells, which included autologous adipose-derived stem cells (35; 67%), autologous bone marrow-derived stem cells (8; 15%), amniotic stem cells (2; 4%), peripheral blood-derived stem cells (2; 4%), umbilical cord blood stem cells (2; 4%), allogenic bone marrow-derived stem cells (1; 2%), placental stem cells (1; 2%), and xenocells (1; 2%). The most commonly marketed ocular conditions included macular degeneration (35), optic neuritis (18), retinitis pigmentosa (17), and diabetic retinopathy (16). The most common routes of administration were intravenous (22) and "unspecified" (12), however other companies listed more ocular-specific routes such as intravitreal injections (2), retrobulbar injections (2), eye injections (2), retrofundal injection (1), subtenon injection (1), intraocular injection with vitrectomy (1), and eye drops (1). The cost of advertised "cell therapy" ranged from $4,000 to $10,500. CONCLUSIONS: "Cell therapy" for ocular conditions is readily available via direct-to-consumer marketing strategies across the United States. The "cells" are harvested from numerous sources and administered through different methods for multiple ocular conditions at these "cell therapy" clinics. Limited data for these treatments necessitates advocating caution to physicians and patients about treatments offered at commercial "cell therapy" clinics. PMID: 30904542 [PubMed - as supplied by publisher]
Read more...

Quick Contact Form